Status Epilepticus - Pipeline Review, H2 2016

  • ID: 3821647
  • Drug Pipelines
  • 65 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Sage Therapeutics, Inc.
  • Shire Plc
  • MORE
Status Epilepticus - Pipeline Review, H2 2016

Summary

‘Status Epilepticus - Pipeline Review, H2 2016’, provides an overview of the Status Epilepticus pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Status Epilepticus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Status Epilepticus and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Status Epilepticus
- The report reviews pipeline therapeutics for Status Epilepticus by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Status Epilepticus therapeutics and enlists all their major and minor projects
- The report assesses Status Epilepticus therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Status Epilepticus

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Status Epilepticus
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Status Epilepticus pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Sage Therapeutics, Inc.
  • Shire Plc
  • MORE
List of Figures

Introduction

Report Coverage

Status Epilepticus Overview

Therapeutics Development

Pipeline Products for Status Epilepticus - Overview

Pipeline Products for Status Epilepticus - Comparative Analysis

Status Epilepticus - Therapeutics under Development by Companies

Status Epilepticus - Therapeutics under Investigation by Universities/Institutes

Status Epilepticus - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Status Epilepticus - Products under Development by Companies

Status Epilepticus - Products under Investigation by Universities/Institutes

Status Epilepticus - Companies Involved in Therapeutics Development

Marinus Pharmaceuticals, Inc.

Sage Therapeutics, Inc.

Shire Plc

Status Epilepticus - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AMPX-0079 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosphenytoin sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ganaxolone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LSPGR-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

midazolam hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAGE-217 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SAGE-689 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sepranolone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TG-4155 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Status Epilepticus - Dormant Projects

Status Epilepticus - Product Development Milestones

Featured News & Press Releases

Jun 22, 2016: Marinus Pharmaceuticals Doses First Subject in Phase 1 Clinical Trial for Ganaxolone IV

Jun 13, 2016: Marinus Pharmaceuticals Announces Top-Line Results from Phase 3 Trial in Adult Focal Onset Seizures

Apr 19, 2016: Marinus Pharmaceuticals Ganaxolone IV Demonstrates Robust Efficacy in Benzodiazepine-Resistant Model of Status Epilepticus

Apr 17, 2016: Sage Therapeutics Expands Scientific, Clinical and Burden of Illness Data for SAGE-547 in SRSE and Essential Tremor at the 2016 American Academy of Neurology Annual Meeting

Apr 15, 2016: Marinus Pharmaceuticals Receives FDA Orphan Drug Designation for Ganaxolone IV to Treat Status Epilepticus

Apr 12, 2016: Marinus Pharmaceuticals to Present Ganaxolone IV Data at American Academy of Neurology Annual Meeting

Mar 03, 2016: Sage Therapeutics to Present SAGE-547 Clinical Data and SRSE Health Economic Data in Five Abstracts at the American Academy of Neurology 2016 Annual Meeting

Dec 15, 2015: SAGE Updates Guidance for Top-Line Results of Phase 3 STATUS Trial of SAGE-547

Dec 02, 2015: SAGE to Present Poster Presentations on SAGE-547 at the American Epilepsy Society 69th Annual Meeting

Aug 17, 2015: SAGE Announces First Patient Treated in Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus

Aug 06, 2015: SAGE Receives Special Protocol Assessment for Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus

Jun 09, 2015: SAGE Therapeutics Announces Positive Top-Line Data in Exploratory Trial of SAGE-547 in Postpartum Depression

May 14, 2015: SAGE Therapeutics Achieves 77 Percent Response Rate in Completed Phase 1/2 Clinical Trial of SAGE-547 in Super-Refractory Status Epilepticus

Apr 22, 2015: Ligand Earns Milestone from SAGE Therapeutics for SAGE-547

Apr 20, 2015: SAGE Therapeutics Announces First Patient Treated Under Phase 3 Expanded Access Protocol to Evaluate SAGE-547 in Patients With Super-Refractory Status Epilepticus

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for Status Epilepticus, H2 2016

Number of Products under Development for Status Epilepticus - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Status Epilepticus - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016

Status Epilepticus - Pipeline by Sage Therapeutics, Inc., H2 2016

Status Epilepticus - Pipeline by Shire Plc, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Status Epilepticus - Dormant Projects, H2 2016 50List of Figures

Number of Products under Development for Status Epilepticus, H2 2016

Number of Products under Development for Status Epilepticus - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Targets, H2 2016

Number of Products by Stage and Targets, H2 2016

Number of Products by Mechanism of Actions, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Marinus Pharmaceuticals, Inc.
Sage Therapeutics, Inc.
Shire Plc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll